CRYOPORT, INC. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-03-31: Measure Revenue.
- 2023-03-31: Measure Adjusted EBITDA.
- 2023-03-31: Measure Total Stockholder Return.
- 2024-04-03: Measure Revenue.
| Proxy filed | Measure |
|---|---|
| 2023-03-31 | Revenue |
| 2023-03-31 | Adjusted EBITDA |
| 2023-03-31 | Total Stockholder Return |
| 2024-04-03 | Revenue |
| 2024-04-03 | Adjusted EBITDA |
| 2024-04-03 | Total Stockholder Return |
| 2025-04-25 | Revenue |
| 2025-04-25 | Adjusted EBITDA |
| 2025-04-25 | TSR |
| 2026-04-22 | Revenue |
| 2026-04-22 | Adjusted EBITDA |
| 2026-04-22 | TSR |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |